Medicament for treatment of non-insulin dependent diabetes mellitus, hypertension and/or metabolic syndrome

Abstract

A substance including the chemical structures of bicyclo [3.2.1]octan or the chemical structures of kaurene for the use in a dietary supplementation or as a constituent in a medicament for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome. The unique chemical structures of bicyclo [3.2.1]octan alone or in a kaurene structure provides the substances, such as e.g. steviol, isosteviol and stevioside with the capability of enhancing or potentiating the secretion of insulin in a plasma glucose dependent manner. The substances including these unique chemical structures also have the capability of reducing the glucagon concentration in the blood and/or lowering the blood pressure thereby providing a self-regulatory treatment system for non-insulin dependent diabetes mellitus and/or hypertension. In a combination drug which also comprise a soy protein, and/or soy fiber and/or at least one isoflavone these substances act synergistically and such combination drugs are highly useful both prophylacticly or directly in the treatment of e.g. the metabolic syndrome and obesity and has due to the self-regulatory effect a widespread applicability as a dietary supplementation.

1 . A method of treating non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome, said method comprising administering a substance selected from the group consisting of steviol and isosteviol to a patient in need thereof in a therapeutically effective amount. 
   
   
       2 . The method according to  claim 1 , wherein the substance is steviol. 
   
   
       3 . The method according to  claim 1 , wherein the substance is isosteviol. 
   
   
       4 . The method according to  claim 1 , wherein the substance is isolated from a plant source. 
   
   
       5 . The method according to  claim 1 , wherein the substance provides an insulin stimulating effect that is dependent on the plasma glucose concentration. 
   
   
       6 . The method according to  claim 5 , wherein the plasma glucose concentration is above 6 mmol/l. 
   
   
       7 . The method according to  claim 1 , wherein the substance controls, regulates and adjusts the plasma glucose concentration to a normal level in a non-insulin dependent diabetes mellitus patient. 
   
   
       8 . The method according to  claim 1 , wherein at plasma glucose concentrations above 6 mmol/l, the treatment provides an elevated plasma insulin concentration resulting in an immediate suppression of the plasma glucose concentration thereby keeping this at a normal level. 
   
   
       9 . The method according to  claim 1 , wherein the treatment is a stimulation of the insulin secretion in a mammal afflicted with non-insulin dependent diabetes mellitus, wherein the stimulation of the insulin secretion is initiated by the presence of a plasma glucose concentration of 6 mmol/l or larger. 
   
   
       10 . The method according to  claim 1 , wherein the substance is administered orally. 
   
   
       11 . The method according to  claim 1 , wherein the substance is administered intravenously, subcutaneously or intramuscularly. 
   
   
       12 . The method according to  claim 1 , wherein the substance is administered in combination with at least one soy protein alone or in combination with at least one isoflavone. 
   
   
       13 . A method of prophylactically treating the metabolic syndrome, said method comprising administering a substance selected from the group consisting of steviol and isosteviol in combination with at least one soy protein alone, or in combination with at least one isoflavone, to a patient in a risk group in a prophylactically effective amount.